Boronic acids as probes for investigation of allosteric modulation of the chemokine receptor CXCR3

ACS Chemical Biology

Volumn 9, Issue 11, 2014, Pages 2664-2677

  Bernat, Viachaslau ^a,b   Admas, Tizita Haimanot ^a   Brox, Regine ^a   Heinemann, Frank W ^a   Tschammer, Nuska ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORONIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANINE NUCLEOTIDE BINDING PROTEIN; RADIOLIGAND; CXCR3 PROTEIN, HUMAN; MOLECULAR PROBE;

ALLOSTERISM; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; EMBRYO; HEK293 CELL LINE; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; MUTAGENESIS; NUCLEOPHILICITY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN-FRAGMENT COMPLEMENTATION ASSAY; RECEPTOR AFFINITY; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; CHEMISTRY; MOLECULAR PROBE;

ALLOSTERIC REGULATION; BORONIC ACIDS; MOLECULAR PROBES; RECEPTORS, CXCR3;

EID: 84923337072     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500678c     Document Type: Article

References (57)

1. Kenakin, T., and Miller, L. J. (2010) Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304.
2. Wootten, D., Christopoulos, A., and Sexton, P. M. (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discovery 12, 630-644.
3. Nussinov, R., and Tsai, C.-J. (2013) Allostery in disease and in drug discovery. Cell 153, 293-305.
4. Christopoulos, A., and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374.
5. Kenakin, T. (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discovery 4, 919-927.
6. Kenakin, T. P. (2009) '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol. Sci. 30, 460-469.
7. Watson, C., Jenkinson, S., Kazmierski, W., and Kenakin, T. (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67, 1268-1282.
8. Maeda, K., Nakata, H., Koh, Y., Miyakawa, T., Ogata, H., Takaoka, Y., Shibayama, S., Sagawa, K., Fukushima, D., Moravek, J., Koyanagi, Y., and Mitsuya, H. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78, 8654-8662.
9. Lacotte, S., Brun, S., Muller, S., and Dumortier, H. (2009) CXCR3, inflammation, and autoimmune diseases. Ann. N. Y. Acad. Sci. 1173, 310-317.
10. Clark-Lewis, I., Mattioli, I., Gong, J.-H., and Loetscher, P. (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J. Biol. Chem. 278, 289-295.
11. Groom, J. R., and Luster, A. D. (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207-215.
12. Rajagopal, S., Bassoni, D. L., Campbell, J. J., Gerard, N. P., Gerard, C., and Wehrman, T. S. (2013) Biased agonism as a mechanism for differential signaling by chemokine receptors. J. Biol. Chem. 288, 35039-35048.
13. Wijtmans, M., Verzijl, D., Leurs, R., de Esch, I. J. P., and Smit, M. J. (2008) Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 3, 861-872.
14. Berry, K., Friedrich, M., Kersey, K., Stempien, M. J., Wagner, F., van Lier, J. J., Sabat, R., and Wolk, K. (2004) Evaluation of T0906487, a CXCR3 antagonist, in a phase 2a psoriasis trial. Inflammation Res. Suppl. 53, S222.
15. Tonn, G. R., Wong, S. G., Wong, S. C., Johnson, M. G., Ma, J., Cho, R., Floren, L. C., Kersey, K., Berry, K., Marcus, A. P., Wang, X., Van Lengerich, B., Medina, J. C., Pearson, P. G., and Wong, B. K. (2009) An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3, 4-dihydro-pyrido[2, 3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects af. Drug Metab. Dispos. 37, 502-513.
16. Henne, K. R., Tran, T. B., Vandenbrink, B. M., Rock, D. A., Aidasani, D. K., Subramanian, R., Mason, A. K., Stresser, D. M., Teffera, Y., Wong, S. G., Johnson, M. G., Chen, X., Tonn, G. R., and Wong, B. K. (2012) Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause timedependent inhibition of the enzyme. Drug Metab. Dispos. 40, 1429-1440.
17. Wu, B., Chien, E. Y. T., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R. A., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V., and Stevens, R. C. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071.
18. Zhu, L., Miao, S., Tonn, G., Schall, T., Wang, X., Dairaghi, D., Johnson, M., Collins, T., Ebsworth, K., Liu, J., Lawrence, C., Huang, A., Li, A.-R., Fu, Z., Medina, J., Xu, F., Sablan, E., Marcus, A., Danao, J., Sullivan, T., Xu, Q., and Kumer, J. (2007) Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg. Med. Chem. Lett. 17, 3339-3343.
19. Liu, J., Fu, Z., Li, A.-R., Johnson, M., Zhu, L., Marcus, A., Danao, J., Sullivan, T., Tonn, G., Collins, T., and Medina, J. (2009) Optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg. Med. Chem. Lett. 19, 5114-5118.
20. Dzhekieva, L., Rocaboy, M., Kerff, F., Charlier, P., Sauvage, E., and Pratt, R. F. (2010) Crystal structure of a complex between the Actinomadura R39 DD-peptidase and a peptidoglycan-mimetic boronate inhibitor: interpretation of a transition state analogue in terms of catalytic mechanism. Biochemistry 49, 6411-6419.
21. Zervosen, A., Herman, R., Kerff, F., Herman, A., Bouillez, A., Prati, F., Pratt, R. F., Frere, J.-M., Joris, B., Luxen, A., Charlier, P., and Sauvage, E. (2011) Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J. Am. Chem. Soc. 133, 10839-10848.
22. Singh, J., Petter, R. C., Baillie, T. a, and Whitty, A. (2011) The resurgence of covalent drugs. Nat. Rev. Drug Discovery 10, 307-317.
23. Gardner, R. C., Assinder, S. J., Christie, G., Mason, G. G., Markwell, R., Wadsworth, H., McLaughlin, M., King, R., Chabot-Fletcher, M. C., Breton, J. J., Allsop, D., and Rivett, A. J. (2000) Characterization of peptidyl boronic acid inhibitors of mammalian 20 and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem. J. 346(Pt 2), 447-454.
24. Dick, L. R., and Fleming, P. E. (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discovery Today 15, 243-249.
25. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D.-L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617.
26. Hall, D. G. (2011) Structure, Properties, and Preparation of Boronic Acid Derivatives, in Boronic Acids: Preparation and Applications in Organic Synthesis, Medicine and Materials (Hall, D. G., Ed.) 2nd ed., pp 1-133, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
27. Xu, Y., Nakajima, Y., Ito, K., Zheng, H., Oyama, H., Heiser, U., Hoffmann, T., Gartner, U.-T., Demuth, H.-U., and Yoshimoto, T. (2008) Novel inhibitor for prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis and details of substrate-recognition mechanism. J. Mol. Biol. 375, 708-719.
28. Chen, Y., Minasov, G., Roth, T. A., Prati, F., and Shoichet, B. K. (2006) The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J. Am. Chem. Soc. 128, 2970-2976.
29. Lienhard, G. E., and Koehler, K. A. (1971) 2-Phenylethaneboronic acid, a possible transition-state analog for chymotrypsin. Biochemistry 10, 2477-2483.
30. Stoll, V. S., Eger, B. T., Hynes, R. C., Martichonok, V., Jones, J. B., and Pai, E. F. (1998) Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin Carlsberg complexes. Biochemistry 37, 451-462.
31. Kwatra, M. M., Leung, E., Hosey, M. M., and Green, R D. (1987) N6-Phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors. J. Med. Chem. 30, 954-956.
32. Samanen, J., Narindray, D., Adams, W., Cash, T., Yellin, T., and Regoli, D. (1988) Effects of D-amino acid substitution on antagonist activities of angiotensin II analogs. J. Med. Chem. 31, 510-516.
33. Samanen, J., Cash, T., Narindray, D., Brandeis, E., Yellin, T., and Regoli, D. (1989) The role of position four in angiotensin II antagonism: a structure-activity study. J. Med. Chem. 32, 1366-1370.
34. Bernat, V., Heinrich, M. R, Baumeister, P., Buschauer, A, and Tschammer, N. (2012) Synthesis and application of the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3. ChemMedChem 7, 1481-1489.
35. Keov, P., Sexton, P. M., and Christopoulos, A (2011) Neuropharmacology allosteric modulation of G protein-coupled receptors: A pharmacological perspective. Neuropharmacology 60, 24-35.
36. Molander, G. A., and Cooper, D. J. (2008) Functionalization of organotrifluoroborates: reductive amination. J. Org. Chem. 73, 3885-3891.
37. Pedersen, D. S., and Rosenbohm, C. (2001) Dry column vacuum chromatography. Synthesis (Stuttgart) 2001, 2431-2434.
38. Nedjai, B., Li, H., Stroke, I. L., Wise, E. L., Webb, M. L., Merritt, J. R, Henderson, I., Klon, A. E., Cole, A. G., Horuk, R, Vaidehi, N, and Pease, J. E. (2012) Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br. J. Pharmacol. 166, 912-923.
39. Scholten, D. J. (2012) Chemokine Receptors CXCR3 and CXCR7: Allosteric Ligand Binding, Biased Signaling, and Receptor Regulation, Vrije Universiteit, Amsterdam.
40. Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815.
41. Benkert, P., Tosatto, S. C. E., and Schomburg, D. (2008) QMEAN: A comprehensive scoring function for model quality assessment. Proteins 71, 261-277.
42. Krieger, E., Koraimann, G, and Vriend, G (2002) Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins: Struct., Funct., Bioinf. 47, 393-402.
43. Jacobson, M. P., Friesner, R A., Xiang, Z., and Honig, B. (2002) On the role of the crystal environment in determining protein sidechain conformations. J. Mol. Biol. 320, 597-608.
44. Trott, O., and Olson, A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461.
45. Tan, Q., Zhu, Y., Li, J. J., Chen, Z., Han, G W., Kufareva, I., Li, T., Ma, L., Fenalti, G, Zhang, W., Xie, X., Yang, H, Jiang, H, Cherezov, V, Liu, H, Stevens, R C., Zhao, Q., and Wu, B. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387-1390.
46. Rosenkilde, M. M., Gerlach, L.-O., Jakobsen, J. S., Skerlj, R T., Bridger, G J., and Schwartz, T. W. (2004) Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 279, 3033-3041.
47. Bordo, D., and Argos, P. (1991) Suggestions for "safe" residue substitutions in site-directed mutagenesis. J. Mol. Biol. 217, 721-729.
48. Verzijl, D., Storelli, S., Scholten, D. J., Bosch, L., Reinhart, T. a, Streblow, D. N, Tensen, C. P., Fitzsimons, C. P., Zaman, G J. R, Pease, J. E., de Esch, I. J. P., Smit, M. J., and Leurs, R (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J. Pharmacol. Exp. Ther. 325, 544-555.
49. Scholten, D. J., Roumen, L., Wijtmans, M., Verkade-Vreeker, M. C. A., Custers, H, Lai, M., de Hooge, D., Canals, M., de Esch, I. J. P., Smit, M. J., de Graaf, C., and Leurs, R (2014) Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211. Mol. Pharmacol. 85, 116-126.
50. Rahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K. S., Durand, G., Pucci, B., Trinquet, E., Zwier, J. M., Deupi, X., Bron, P., Baneres, J.-L., Mouillac, B., and Granier, S. (2012) Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 109, 6733-6738.
51. Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T. A., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549-555.
52. Rasmussen, S. G. F., Choi, H.-J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. K., Gellman, S. H., Pautsch, A., Steyaert, J., Weis, W. I., and Kobilka, B. K. (2011) Structure of a nanobody-stabilized active state of the β (2) adrenoceptor. Nature 469, 175-180.
53. Helices, T., Steen, A., Thiele, S., Guo, D., Hansen, L. S., Frimurer, T. M., and Rosenkilde, M. M. (2013) Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. J. Biol. Chem. 288, 12511-21.
54. O'Boyle, G., Fox, C. R. J., Walden, H. R., Willet, J. D. P., Mavin, E. R., Hine, D. W., Palmer, J. M., Barker, C. E., Lamb, C. A., Ali, S., and Kirby, J. A. (2012) Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc. Natl. Acad. Sci. U. S. A. 109, 4598-4603.
55. Scholten, D. J., Canals, M., Wijtmans, M., de Munnik, S., Nguyen, P., Verzijl, D., de Esch, I. J. P., Vischer, H. F., Smit, M. J., and Leurs, R. (2012) Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3. Br. J. Pharmacol. 166, 898-911.
56. Lowry, O. H., Rosebrough, N. J., Farr, L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
57. Schrodinger, LLC (2010) The PyMOL Molecular Graphics System, Version 1.3r1.